3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
13
Genitourinary
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
4
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Gastric Cancer
1
Interventions
pembrolizumab
6
Cisplatin
5
Gemcitabine
4
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Hyperthermic Intraperitoneal Chemotherapy
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
veliparib
2
aflibercept
2
X-Rays
2
Temozolomide
2
Taxes
2
SS1(dsFv)PE38
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Oxaliplatin
2
Nivolumab
2
Irinotecan
2
Interleukin-12 Subunit p35
2
Immunoglobulin G
2
Gene Expression Profiling
2
Fluorouracil
2
Drug Therapy
2
Doxorubicin
2
Disulfides
2
Biopsy
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
rucaparib
×
Gastrointestinal
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts